trending Market Intelligence /marketintelligence/en/news-insights/trending/-1ozLo8mdraXZd_-qR8NxA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

ThromboGenics shareholders approve name change

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ThromboGenics shareholders approve name change

Belgium-based biotechnology company ThromboGenics NV gained shareholders approval to change its name to Oxurion NV at an extraordinary general meeting held Sept. 3.

ThromboGenics' lead product JETREA is used to treat declining visual function due to vitreomacular traction syndrome.

The company's ticker on Euronext Brussels will change to OXUR from THR.

ThromboGenics said in a statement that it will also change its corporate website in connection with the name change.